Literature DB >> 7196861

High-dose platinum for the treatment of refractory ovarian cancer.

H W Bruckner, R Wallach, C J Cohen, G Deppe, B Kabakow, L Ratner, J F Holland.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7196861     DOI： 10.1016/0090-8258(81)90095-0

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN： 0090-8258            Impact factor:   5.482


× No keyword cloud information.
  7 in total

Review 1.  Developing new drugs for ovarian cancer: a challenging task in a changing reality.

Authors:  R M Canetta; S K Carter
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

2.  Phase II study of pirarubicin combined with cisplatin in recurrent ovarian cancer.

Authors:  A du Bois; H G Meerpohl; H Madjar; D Spinner; P Dall; J Pfisterer; T Bauknecht
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

3.  High-dose cisplatin in disseminated melanoma: a comparison of two schedules.

Authors:  J E Mortimer; S Schulman; J S MacDonald; K Kopecky; G Goodman
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 4.  Cisplatin overdose: toxicities and management.

Authors:  Roger Y Tsang; Turki Al-Fayea; Heather-Jane Au
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

5.  Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours.

Authors:  A S Planting; M E van der Burg; M de Boer-Dennert; G Stoter; J Verweij
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640

6.  Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours.

Authors:  J H Schellens; J Ma; A S Planting; M E van der Burg; E van Meerten; M de Boer-Dennert; P I Schmitz; G Stoter; J Verweij
Journal:  Br J Cancer       Date:  1996-06       Impact factor: 7.640

7.  A randomised study of carboplatin vs sequential ifosfamide/carboplatin for patients with FIGO stage III epithelial ovarian carcinoma. The London Gynaecologic Oncology Group.

Authors:  T J Perren; E Wiltshaw; P Harper; M Slevin; R Stein; S Tan; M Gore; I J Fryatt; P R Blake
Journal:  Br J Cancer       Date:  1993-12       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.